

IFW

DOCKET NO.: C1037.70038US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/735,592
Confirmation No.: 2533
Filed: December 11, 2003
For: 5' CPG NUCLEIC ACIDS AND METHODS OF USE
Examiner: Not Yet Assigned
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 7th day of July, 2004.


Kristin J. Ketelhut

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449 with cited references
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Krieg et al., Applicant

By: 
Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617)646-8000

Docket No. C1037.70038US01
Date: July 7, 2004
xNDDx




DOCKET NO: C1037.70038US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No: 10/735,592
Confirmation No: 2533
Filed: December 11, 2003
For: 5' CPG NUCLEIC ACIDS AND METHODS OF USE
Examiner: Not Yet Assigned
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 7th day of July, 2004.


Kristin J. Ketelhut

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
C1037.70013US01	10/831,778	April 23, 2004	Bratzler et al.
C1037.70039US01	10/816,220	April 1, 2004	McCluskie et al.
C1037.70041US00	10/613,749	July 3, 2003	Krieg
C1037.70042US00	10/613,524	July 3, 2003	Krieg
C1037.70043US00	10/613,739	July 3, 2003	Krieg
C1037.70044US00	10/613,736	July 3, 2003	Krieg
C1037.70045US00	10/613,228	July 3, 2003	Krieg
C1037.70048US00	10/644,052	August 19, 2003	Jurk et al.
C1037.70049US00	10/643,141	August 18, 2003	Hutcherson et al.
C1037.70051US00	10/666,733	September 19, 2003	Bratzler et al.
C1037.70052US00	10/668,050	September 22, 2003	Bratzler et al.
C1039.70020US00	09/337,584	June 21, 1999	Krieg et al.
C1039.70021US01	10/719,493	November 21, 2003	Krieg et al.
C1039.70022US00	09/337,893	June 21, 1999	Krieg
C1039.70035US00	09/669,187	September 25, 2000	Krieg et al.
C1039.70036US00	09/559,140	April 27, 2000	Noll et al.
C1039.70041US00	09/655,319	September 5, 2000	Krieg et al.
C1039.70042US00	09/630,319	July 31, 2000	Krieg et al.
C1039.70043US00	09/629,477	July 31, 2000	Krieg et al.
C1039.70044US00	09/672,126	September 27, 2000	Hartmann et al.
C1039.70048US01	10/769,282	January 30, 2004	Krieg et al.
¹ C1039.70048US02	10/817,165	April 2, 2004	Krieg et al.
¹ C1039.70048US03	10/831,647	April 23, 2004	Krieg et al.
¹ C1039.70048US04	Not Yet Assigned	May 15, 2004	Krieg et al.
C1039.70057US00	09/965,101	September 26, 2001	Davis et al.

¹Copy not enclosed; see C1039.70048US01, Serial No. 10/769,282 for identical specification

<u>Docket No.</u>	<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>
² C1039.70057US01	Not Yet Assigned	May 3, 2004	Davis et al.
C1039.70058US01	10/831,775	April 23, 2004	Davis et al.
C1039.70062US00	10/187,489	July 2, 2002	Krieg et al.
³ C1039.70069US00	10/314,578	December 9, 2002	Krieg et al.
C1039.70070US00	10/382,822	March 6, 2003	Krieg et al.
C1039.70071US00	10/435,656	May 9, 2003	Krieg et al.
C1039.70072US00	10/434,696	May 9, 2003	Davis et al.
C1039.70073US00	10/743,625	December 22, 2003	Krieg et al.
C1039.70075US00	10/613,916	July 3, 2003	Krieg et al.
C1039.70077US00	10/619,279	July 14, 2003	Krieg
C1039.70078US00	10/627,331	July 25, 2003	Krieg et al.
C1039.70079US00	10/627,413	July 25, 2003	Krieg et al.
C1039.70082US00	10/631,676	July 30, 2003	Krieg et al.
C1039.70083US00	10/690,495	October 21, 2003	Krieg et al.
⁴ C1039.70083US01	10/769,626	January 30, 2004	Krieg et al.
⁴ C1039.70083US02	10/787,737	February 26, 2004	Krieg et al.
⁴ C1039.70083US03	10/788,199	February 26, 2004	Krieg et al.
⁴ C1039.70083US04	10/788,191	February 26, 2004	Krieg et al.
⁴ C1039.70083US05	10/789,536	February 26, 2004	Krieg et al.
⁴ C1039.70083US06	10/789,051	February 26, 2004	Krieg et al.
⁴ C1039.70083US07	10/789,353	February 26, 2004	Krieg et al.
C1039.70084US00	10/649,584	August 25, 2003	Krieg et al.
C1040.70006US00	09/316,199	May 21, 1999	McCluskie et al.
C1041.70002US00	09/241,653	February 2, 1999	Wagner et al.
C1041.70005US00	09/355,254	February 22, 2000	Wagner et al.
⁵ C1041.70005US01	10/811,226	March 26, 2004	Wagner et al.
C1041.70010US00	09/786,436	March 2, 2001	Wagner et al.
C1041.70024WO00	Not Yet Assigned	April 22, 2004	Vollmer et al.
C1041.70035US00	10/373,381	February 25, 2003	Wagner et al.
C1041.70040US00	10/666,844	September 19, 2003	Lipford et al.

²Copy not enclosed; see C1039.70057US00, Serial No. 09/965,101 for identical specification

³Copy not enclosed; see C1039.70035US00, Serial No. 09/669,187 for identical specification

⁴Copy not enclosed; see C1039.70083US00, Serial No. 10/690,495 for identical specification

⁵Copy not enclosed; see C1041.70005US00, Serial No. 09/355,254 for identical specification

The following are remarks concerning the other information cited:

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Krieg et al., *Applicant*

By: 
Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. C1037.70038US01

Date: July 7, 2004

XNDDX



FORM PTO 449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	1	of	12				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1**	5,023,243		Tullis	
	A2**	5,248,670		Draper, et al.	
	A3**	5,268,365		Rudolph, et al.	
	A4**	5,543,152		Webb, et al.	
	A5**	5,595,756		Bally, et al.	
	A6**	5,663,153		Hutcherson, et al.	
	A7**	5,679,647		Carson, et al.	
	A8**	5,705,385		Bally, et al.	
	A9**	5,723,335		Hutcherson, et al.	
	A10**	5,753,613		Ansell, et al.	
	A11**	5,756,097		Landucci, et al.	
	A12**	5,766,920		Babbitt, et al.	
	A13**	5,780,448		Davis	
	A14**	5,785,992		Ansell, et al.	
	A15**	5,786,189		Locht, et al.	
	A16**	5,804,566		Carson, et al.	
	A17**	5,814,335		Webb, et al.	
	A18**	5,837,243		Deo, et al.	
	A19**	5,849,719		Carson, et al.	
	A20**	5,932,556			
	A21**	5,965,542		Wasan, et al.	
	A22**	5,976,567		Wheeler, et al.	
	A23**	5,981,501		Wheeler, et al.	
	A24**	6,027,726		Ansell	
	A25**	6,110,745		Zhang, et al.	
	A26**	6,174,872		Carson, et al.	
	A27**	6,426,336	B1	Carson, et al.	
	A28**	6,498,148	B1	Raz	
	A29**	6,514,948	B1	Raz, et al.	
	A30**	6,534,062		Raz, et al.	
	A31**	6,544,518		Friede, et al.	
	A32**	6,552,006	B2	Raz, et al.	
	A33**	6,562,798	B1	Schwartz	05-13-2003
	A34**	6,589,940	B1	Raz, et al.	
	A35**	6,610,661		Carson, et al.	08-26-2003
	A36**	2001/0034330		Kensil	
	A37**	2001/0036462		Fong et al.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned			
Sheet	2	of	12						

	A38**	2003/0072762		Van de Winkel et al.	
	A39**	2003/0119774		Foldvari et al.	
	A40**	2003/0125279		Junghans et al.	
	A41**	2003/0125292		Semple et al.	
	A42**	2003/0138413	A1	Vicari et al.	
	A43**	2003/0186912		Agrawal	
	A44**	6,194,388	B1	Krieg et al.	
	A45**	6,207,646	B1	Krieg et al.	03-27-2001
	A46**	6,214,806	B1	Krieg et al.	04-10-2001
	A47**	6,218,371	B1	Krieg et al.	04-17-2001
	A48**	6,239,116	B1	Krieg et al.	05-29-2001
	A49**	6,339,068	B1	Krieg et al.	01-15-2002
	A50**	6,406,705	B1	Davis et al.	06-18-2002
	A51**	6,429,199	B1	Krieg et al.	08-06-2002
	A52**	6,653,292	B1	Krieg et al.	11-25-2003
	A53**	6,727,230	B1	Hutcherson et al.	04-27-2004
	A54**	2001/0044416	A1	McCluskie et al.	11-22-2001
	A55**	2002/0064515	A1	Krieg et al.	05-30-2002
	A56**	2002/0091097	A1	Bratzler et al.	07-11-2002
	A57**	2002/0156033	A1	Bratzler et al.	10-24-2002
	A58**	2002/0165178	A1	Schetter et al.	11-07-2002
	A59**	2002/0164341	A1	Davis et al.	11-07-2002
	A60**	2002/0198165	A1	Bratzler et al.	12-26-2002
	A61**	2003/0026782	A1	Krieg et al.	02-06-2003
	A62**	2003/0026801	A1	Weiner et al.	02-06-2003
	A63**	2003/0050261	A1	Krieg et al.	03-13-2003
	A64**	2003/0050263	A1	Krieg et al.	03-13-2003
	A65**	2003/0050268	A1	Krieg et al.	03-13-2003
	A66**	2003/0055014	A1	Bratzler	03-20-2003
	A67**	2003/0087848	A1	Bratzler et al.	05-08-2003
	A68**	2003/0091599	A1	Davis et al.	05-15-2003
	A69**	2003/0100527	A1	Krieg et al.	05-29-2003
	A70**	2003/0104523	A1	Bauer et al.	06-05-2003
	A71**	2003/0139364	A1	Krieg et al.	07-24-2003
	A72**	2003/0148316	A1	Lipford et al.	08-07-2003
	A73**	2003/0148976	A1	Krieg et al.	08-07-2003
	A74**	2003/0166001	A1	Lipford	09-04-2003
	A75**	2003/0181406	A1	Schetter et al.	09-25-2003
	A76**	2003/0191079	A1	Krieg et al.	10-09-2003
	A77**	2003/0232074	A1	Lipford et al.	12-18-2003
	A78**	2004/0009949	A1	Krieg	01-15-2004

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	3	of	12				

	A79**	6,613,751			09-02-2003
	A80**	2002/0028784			03-07-2002
	A81**	2001/0046967			11-29-2001
	A82**	2002/0042387			04-11-2002
	A83**	2002/0055477			
	A84**	2002/0098199			07-25-2002
	A85**	2002/0107212			
	A86**	2003/0022852			01-30-2003
	A87**	2003/0059773			03-27-2003
	A88**	2003/0078223			04-24-2003
	A89**	2003/0092663			05-15-2003
	A90**	2003/0119773			
	A91**	2003/0129251			
	A92**	2003/0130217			07-10-2003
	A93**	2003/0133988			07-17-2003
	A94**	2003/0175731			09-18-2003
	A95**	2003/0176389			09-18-2003
	A96**	2003/0199466			10-23-2003
	A97**	2003/0216340			
	A98**	2003/0225016			12-04-2003
	A99**	2003/0232780			12-18-2003
	A100**	2004/0006010			
	A101**	2004/0006034			01-08-2004
	A102**	2004/0009942			01-15-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	EP	0 302 758	A1	New England Medical Center Hospitals, Inc.		
	B2	EP	0 468 520		Mitsui Toatsu Chemicals, Inc.		
	B3	WO	91/12811	A1	ISIS Pharmaceuticals Inc.		
	B4	WO	92/03456				
	B5	WO	94/19945	A1	ISIS Pharmaceuticals Inc.		
	B6	WO	96/24380		ICN Pharmaceuticals		
	B7	WO	97/28259	A1	The Regents of the University of California		
	B8	WO	98/16247	A1	The Regents of the University of California		
	B9	WO	98/29430		ICN Pharmaceuticals		
	B10	WO	98/32462				
	B11	WO	98/40100	A1	Ottawa Civic Loeb Research Institute		
	B12	WO	98/51278	A2	INEX Pharmaceuticals Corp.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01			
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned			
Sheet	4	of	12						

	B13	WO	98/55495	A2	Dynavax Technologies Corporation		
	B14	WO	99/11275	A2	The Regents of the University of California		
	B15	WO	99/30686				
	B16	WO	99/33493	A1	INEX Pharmaceuticals Corporation		
	B17	WO	99/52549				
	B18	WO	99/55743	A1	INEX Pharmaceuticals Corporation		
	B19	WO	99/62923	A2	Dynavax Technologies Corporation		
	B20	WO	00/03683	A2	INEX Pharmaceuticals Corporation		
	B21	WO	00/06588	A1	University of Iowa Research Foundation		
	B22	WO	00/16804	A1	Dynavax Technologies Corporation		
	B23	WO	00/20039	A1	The Regents of the University of California		
	B24	WO	00/21556	A1	Dynavax Technologies Corporation		
	B25	WO	00/62787	A1	The Regents of the University of California		
	B26	WO	01/02007	A1	The Regents of the University of California		
	B27	WO	01/12223	A2	Dynavax Technologies Corporation		
	B28	WO	01/12804	A2	Hybridon, Inc.		
	B29	WO	01/68077	A2	Dynavax Technologies Corporation		
	B30	WO	01/68078	A2	Dynavax Technologies Corporation		
	B31	WO	01/68103	A2	Dynavax Technologies Corporation		
	B32	WO	01/68116	A2	Dynavax Technologies Corporation		
	B33	WO	01/68117	A2	Dynavax Technologies Corporation		
	B34	WO	01/68143	A2	Dynavax Technologies Corporation		
	B35	WO	01/68144	A2	Dynavax Technologies Corporation		
	B36	WO	02/097478				
	B37	WO	02/102307	A2	Ribapharm		
	B38	WO	02/24225				
	B39	WO	02/26757	A2	Hybridon, Inc.		
	B40	WO	03/020889	A2	3M Innovative Properties Company		
	B41	WO	03/024481	A2	Cytos Biotechnology AG		
	B42	WO	03/030656				
	B43	WO	03/030934				
	B44	WO	03/045428	A2	Medigene Aktiengesellschaft		Y- Abstract Only
	B45	WO	03/094963				
	B46	WO	03/100040	A1	Merck Patent GMBH		
	B47	WO	03/101375				

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	5	of	12				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	AGRAWAL et al., "Antisense oligonucleotides: towards clinical trials", <i>Trends in Biotechnology</i> , 14: 376-387, 1996.	
	C2	ANDERSON et al., "Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides", <i>Cancer Immunology Immunotherapy</i> , 49(9): 459-68, 2000.	
	C3	ANDERSON et al., "TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives", <i>Trends in Pharmacological Science</i> , 15: 324-332, 1994.	
	C4	ASKEW et al., "CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms", <i>Journal of Immunology</i> , 165: 6889-95, 2000.	
	C5	BALLAS et al., "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA", <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
	C6	BATES et al., "Antiproliferative activity of G-rich oligonucleotides correlates with protein binding", <i>Journal of Biological Chemistry</i> , 274: 26369-77, 1999.	
	C7	BAYEVER et al., "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial", <i>Antisense Research & Development</i> , 3: 383-390, 1993.	
	C8	BENIMETSKAYA et al., "Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide", <i>Nucleic Acid Research</i> , 25(3): 2648-56, 1997.	
	C9	BISHOP et al., "Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide", <i>Journal of Biological Chemistry</i> , 271: 5698-5703, 1996.	
	C10	BLAXTER et al., "Genes expressed in <i>Brugia malayi</i> infective third stage larvae", <i>Molecular and Biochemical Parasitology</i> , 77: 77-93, 1996.	
	C11	BOGGS et al., "Characterization and modulation of immune stimulation by modified oligonucleotides", <i>Antisense Nucleic Acid Drug Development</i> , 7(5): 461-71, 1997.	
	C12	BRANDA et al., "Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1", <i>Biochemical Pharmacology</i> , 45(10): 2037-2043, 1993.	
	C13	BRANDA et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides", <i>Journal of Laboratory Clinical Medicine</i> , 128(3): 329-38, 1996.	
	C14	BRAZOLOT-MILLAN et al., "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", <i>Proceedings of the National Academy of Science USA</i> , 95: 15553-15558, 1998.	
	C15	BROIDE et al., "DNA-Based immunization for asthma", <i>International Archives of Allergy and Immunology</i> , 118: 453-456, 1999.	
	C16	BROSSART et al., "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", <i>Blood</i> , 96(9): 3102-8, 2000.	
	C17	BRUNNER et al., "Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo", <i>Journal of Immunology</i> , 165: 6278-6286, 2000.	
	C18	BURGESS et al., "The antiproliferative activity of c-myc and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", <i>Proceedings of the National Academy of Science USA</i> , 92(9): 4051-5, 1995.	
	C19	CAVACINI et al., "Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen", <i>Clinical Cancer Research</i> , 8(2): 368-73, 2002.	
	C20	CHOI et al., "The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant", <i>Vaccine</i> , 20(13-14): 1733-40, 2002.	
	C21	CHU et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity", <i>Journal of Experimental Medicine</i> , 186(10): 1623-31, 1997.	
	C22	CONSTANT et al., "Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches", <i>Annual Reviews in Immunology</i> , 15: 297-322, 1997.	
	C23	CONSTANT et al., "Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands", <i>Science</i> , 264: 267-70, 1994.	
	C24	COSSUM et al., "Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats", <i>Journal of Pharmacological Experimental Theory</i> , 269(1): 89-94, 1994.	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	6	of	12				

	C25	COWDERY et al., "Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides", <i>Journal of Immunology</i> , 156(12): 4570-5, 1996.		
	C26	COWSERT et al., "In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts", <i>Antimicrobial Agents in Chemotherapy</i> , 37: 171-77, 1993.		
	C27	DAHESHIA et al., "Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines", <i>Vaccine</i> , 16(11-12): 1103-1110, 1998.		
	C28	DAPIC et al., <i>Proceedings of AACR</i> , pp. 42 March 2001.		
	C29	DAVIS et al., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", <i>Journal of Immunology</i> , 160(2): 870-6, 1998.		
	C30	DAVIS et al., "CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans", <i>Vaccine</i> , 18; 1920-1924, 2000.		
	C31	DAVIS et al., "Plasmid DNA expression systems for the purpose of immunization", <i>Current Opinions Biotechnology</i> , 8(5): 635-46, 1997.		
	C32	DAVIS et al., "Use of CpG DNA for enhancing specific immune responses", <i>Current Topics in Microbiology Immunology</i> , 247: 171-83, 2000.		
	C33	DEML et al., "Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins", <i>Clinical Chemistry Laboratory Medicine</i> , 37: 199-204 1999.		
	C34	DIAMANTSTEIN et al., "Specific binding of poly(I)-poly(C) to the membrane of murine B lymphocyte subsets", <i>European Journal of Immunology</i> , 8: 896, 1978.		
	C35	DISIS et al., "Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine", <i>Clinical Cancer Research</i> , 5(6): 1289-97, 1999.		
	C36	DISIS et al., "Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines", <i>Journal of Clinical Oncology</i> , 20(11): 2624-32, 2002.		
	C37	DUMAIS et al., "Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge", <i>Journal of Infection and Disease</i> , 186(8): 1098-105, 2002.		
	C38	ELKINS et al., "Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria", <i>Journal of Immunology</i> , 162: 2291-2298, 1999.		
	C39	EL-SHAMI et al., "MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope", <i>European Journal of Immunology</i> , 29(10): 3295-301, 2002.		
	C40	EWEL et al., "Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects", <i>Cancer Research</i> , 52(11): 3005-10, 1992.		
	C41	FREIDAG et al., "CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis", <i>Infection and Immunity</i> , 68: 2948-2953, 2000.		
	C42	GALLICHAN et al., "Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract", <i>The Journal of Immunology</i> , 166: 3451-3457, 2001.		
	C43	HADDEN et al., "Immunostimulants", <i>Trends in Pharmacological Science</i> , 14: 169-174, 1993.		
	C44	HAHM et al., "Efficacy of polyadenylic polyuridylic acid in the treatment of chronic active Hepatitis B", <i>Int J Immunopharmac</i> , 16(3): 217-25, 1994.		
	C45	HALPERN et al., "Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha", <i>Cell Immunology</i> , 167(1): 72-8, 1996.		
	C46	HARRINGTON et al., "Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine", <i>Infection and Immunity</i> , 24: 160, 1979.		
	C47	HARTMANN et al., "CpG DNA and LPS induce distinct patterns of activation in human monocytes", <i>Gene Therapy</i> , 6: 893-903, 1999.		
	C48	HARTMANN et al., "Mechanism and function of a newly identified CpG DNA motif in human primary B cells", <i>Journal of Immunology</i> , 164: 944, 2000.		
	C49	HARTMANN et al., "Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides", <i>Antisense Nucleic Acid Drug Development</i> , 6: 291, 1996.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	7	of	12				

	C50	HARTMANN et al., "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", <i>Journal of Immunology</i> , 164: 1617, 2000.		
	C51	HARTMANN et al., "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", <i>Proceedings of the National Academy of Science USA</i> , 96: 9305-9310, 1999.		
	C52	HAYASHI et al., "Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase", <i>Infection and Immunity</i> , 69: 6156-6164, 2001.		
	C53	HINKULA et al., "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes", <i>Journal of Virology</i> , 71(7): 5528-39, 1997.		
	C54	HOPKIN et al., <i>BioMedNet</i> , Issue 57, 6/25/1999.		
	C55	HUANG et al., "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", <i>Infection and Immunity</i> , 67(12): 6257-6263, 1999.		
	C56	HUGHES et al., <i>Antisense Research Development</i> , 4: 211-15, 1994.		
	C57	HUNG et al., "Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen", <i>Journal of Immunology</i> , 166(9): 5733-40, 2001.		
	C58	IHO et al., "Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro", <i>Journal of Immunology</i> , 163: 3642, 1999.		
	C59	ISHIKAWA et al., "IFN induction and associated changes in splenic leukocyte distribution", <i>Journal of Immunology</i> , 150(9): 3713-27, 1993.		
	C60	IVERSEN et al., "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion", <i>Antisense Research and Development</i> , 4: 43-52, 1994.		
	C61	JAKOB et al., "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA", <i>Journal of Immunology</i> , 161(6): 3042-9, 1998.		
	C62	JAKOB et al., "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses", <i>International Archives of Allergy Immunology</i> , 118(2-4): 457-61, 1999.		
	C63	JOHNSON et al., <i>Immunopharmacology, Infection, and Disease</i> , 291-301, 1987.		
	C64	JONES et al., "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", <i>Vaccine</i> , 17: 3065-3071, 1999.		
	C65	JUFFERMANS et al., "CpG oligodeoxynucleotides enhance host defense during murine tuberculosis", <i>Infection and Immunity</i> , 70: 147-152, 2002.		
	C66	KANDIMALLA et al., "A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif", <i>Proceedings of the National Academy of Science</i> , 100(24): 14303-14308, 2003.		
	C67	KATAOKA et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", <i>Japan Journal of Cancer Research</i> , 83: 244-247, 1992.		
	C68	KERN et al., "Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid", <i>Antimicrobial Agent Chemotherapy</i> , 7: 793, 1975.		
	C69	KIMURA et al., "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN", <i>Journal of Biochemistry</i> , 116(5): 991-994, 1994.		
	C70	KLINE et al., <i>Journal of Investigative Medicine</i> , 44(7): 380A, 1996.		
	C71	KLINE et al., <i>Journal of Investigative Medicine</i> , 45(3): 282A, 1997.		
	C72	KLINE et al., <i>Journal of Investigative Medicine</i> , 45(7): 298A, 1997.		
	C73	KLINE et al., "CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma", <i>Journal of Allergy and Clinical Immunology</i> , 1258-64, 1999.		
	C74	KLINMAN et al., "Immune recognition of foreign DNA: a cure for bioterrorism?", <i>Immunity</i> , 11: 123-129, 1999.		
	C75	KLINMAN et al., "Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection", <i>Infection and Immunity</i> , 67: 5658-5663, 1999.		
	C76	KLINMAN et al., "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety", <i>Springer Seminars in Immunopathology</i> , 22: 173-183, 2000.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	8	of	12				

C77	KLINMAN et al., "Contribution of CpG motifs to the immunogenicity of DNA vaccines", <i>Journal of Immunology</i> , 158(8): 3635-9, 1997.		
C78	KLINMAN et al., "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma", <i>Proceedings of the National Academy of Science USA</i> , 93(7): 2879-83, 1996.		
C79	KOU et al., <i>Alerugi</i> , 43: 482, 1994. Abstract only		
C80	KOVARIK et al., "Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens", <i>Immunology</i> , 102(1): 67-76, 2001.		
C81	KOVARIK et al., <i>The Journal of Immunology</i> , 162: 1611-1617, 1999.		
C82	KRANZER et al. "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming", <i>Immunology</i> , 99: 170, 2000.		
C83	KRIEG et al., "CpG motifs in bacterial DNA and their immune effects", <i>Annual Reviews in Immunology</i> , 20: 709, 2002.		
C84	KRIEG et al., "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> , 48: 303-305, 2000.		
C85	KRIEG et al., "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense Nucleic Acid Drug Development</i> , 6(2): 133-9, 1996.		
C86	KRIEG et al., "Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", <i>Antisense Research and Development</i> , 5: 241, 1995.		
C87	KRIEG et al., <i>Applied Antisense Oligonucleotide Technology</i> , 431-448, 1998.		
C88	KRIEG et al., "CpG DNA: a pathogenic factor in systemic lupus erythematosus?", <i>Journal of Clinical Immunology</i> , 15(6): 284-292, 1995.		
C89	KRIEG et al., "CpG motifs in bacterial DNA trigger direct B-cell activation", <i>Nature</i> , 374: 546-9, 1995.		
C90	KRIEG et al., "Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy", <i>Proceedings of the National Academy of Science</i> , 90: 1048-1052, 1993.		
C91	KRIEG et al., "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> , 6: 23-27, 1998.		
C92	KRIEG et al., "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA", <i>Journal of Laboratory Clinical Medicine</i> , 128(2): 128-33, 1996.		
C93	KRIEG et al., Abstract from 1996 meeting on Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory, September 9-13, 1996. p.116.		
C94	KRIEG et al., "Enhancing vaccines with immune stimulatory CpG DNA", <i>Current Opinions Molecular Theory</i> , 3(1): 15-24, 2001.		
C95	KRIEG et al., "CpG oligonucleotides as immune adjuvants", Ernst Schering Res Found Workshop. 2000;(30):105-18. Review.		
C96	KRIEG et al., "Immune effects and mechanisms of action of CpG motifs", <i>Vaccine</i> , 19(6): 618-22, 2001.		
C97	KRIEG et al. "The role of CpG motifs in innate immunity", <i>Current Opinions Immunology</i> , 12: 35, 2000.		
C98	KRIEG et al., "Mechanism of Action in CpG DNA", <i>Current Topics in Microbiology and Immunology</i> , 247: 1-21, 2000.		
C99	KRIEG et al., "Mechanisms and therapeutic applications of immune stimulatory cpG DNA", <i>Pharmacological Theory</i> , 84: 113, 1999.		
C100	KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", <i>Proceedings of the National Academy of Science</i> , 95: 12631-636, 1998.		
C101	KRIEG et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>Listeria monocytogenes</i> challenge", <i>Journal of Immunology</i> , 161(5): 2428-2434, 1998.		
C102	KROWN et al., <i>Journal of Interferon Research</i> , 3: 281, 1983.		
C103	KROWN et al., "Interferons and interferon inducers in cancer treatment", <i>Seminars in Oncology</i> , 13(2): 207-17, 1986.		
C104	KURAMOTO et al., "Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction", <i>International Immunopharmacology</i> , 14(5): 773-782, 1992.		
C105	KURAMOTO et al., "Oligonucleotide sequences required for natural killer cell activation", <i>Japan Journal of Cancer Research</i> , 83: 1128-1131, 1992.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	9	of	12				

C106	KURAMOTO et al., "In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG", <i>Microbiological Immunology</i> , 33(11): 929-940, 1989.
C107	LALLY et al., "Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading", <i>International Journal of Cancer</i> , 93(6): 841-7, 2001.
C108	LEDERMAN et al., "Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation", <i>Antisense Nucleic Acid Drug Development</i> , 6: 281-9, 1996.
C109	LEE et al., "An oligonucleotide blocks interferon-gamma signal transduction", <i>Transplantation</i> , 62: 1297-1301, 1996.
C110	LEONARD et al., "Conformation of guanine-8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(08A)GCG)", <i>Biochemistry</i> , 31(36): 8415-8420, 1992.
C111	LEVINE et al., "Phase I-II trials of poly IC stabilized with poly-L-lysine", <i>Cancer Treatment Reports</i> , 62: 1907, 1978.
C112	LEVY et al., <i>Journal of Infectious Disease</i> , 133: A256, 1976.
C113	LIAU et al., "Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination", <i>Cancer Research</i> , 62(8): 2287-93, 2002.
C114	LIPFORD et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>European Journal of Immunology</i> , 27(9): 2340-4, 1997.
C115	LIPFORD et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", <i>European Journal of Immunology</i> , 27: 3420-6, 1997.
C116	LIPFORD et al., "Bacterial DNA as immune cell activator", <i>Trends Microbiological</i> , 6(12): 496-500, 1998.
C117	LIU et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor", <i>Blood</i> , 92(10): 3730-3736, 1998.
C118	LOKE et al., "Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis", <i>Current Topics Microbiological Immunology</i> , 141: 282, 1988.
C119	MACAYA et al., "Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution", <i>Proceedings of the National Academy of Science</i> , 90: 3745-9, 1993.
C120	MALANCHERE-BRES et al., "CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice", <i>Journal of Virology</i> , 75(14): 6482-6491, 2001.
C121	MALTESE et al., "Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity", <i>Nucleic Acids Research</i> , 23: 1146-51, 1995.
C122	MANZEL et al., "CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells", <i>Journal of Leukocyte Biology</i> , 66: 817, 1999.
C123	MARKIEWICZ et al., "Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A", <i>International Immunology</i> , 13(5): 625-32, 2001.
C124	MATSON et al., "Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides", <i>Antisense Research and Development</i> , 2(4): 325-30, 1992.
C125	MATSUKURA et al., "Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells", <i>Proceedings of the National Academy of Science USA</i> , 86: 4244-48, 1989.
C126	MCCLUSKIE et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", <i>Journal of Immunology</i> , 161: 4463-6, 1998.
C127	MCCLUSKIE et al., <i>Vaccine</i> , 18: 231-237, 2000.
C128	MCCLUSKIE et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants", <i>Vaccine</i> , 19: 413-422, 2001.
C129	MCCLUSKIE et al., "CpG DNA is an effective oral adjuvant to protein antigens in mice", <i>Vaccine</i> , 19: 950, 2001.
C130	MCCLUSKIE et al., "The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants", <i>Vaccine</i> , 19: 2657-2660, 2001.
C131	MCCLUSKIE et al., "The use of CpG DNA as a mucosal vaccine adjuvant", <i>Current Opinions Investigational Drugs</i> , 2(1): 35-9, 2001.
C132	MCCLUSKIE et al., "Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants", <i>Vaccine</i> , 19(27): 3759-68, 2001.

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	10	of	12				

	C133	MCCLUSKIE et al., "The potential of CpG oligodeoxynucleotides as mucosal adjuvants", <i>Critical Reviews in Immunology</i> , 21(1-3): 103-20, 2001.		
	C134	MCCLUSKIE et al., "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA", <i>FEMS Immunology Medicine Microbiology</i> , 32(3): 179-85, 2002.		
	C135	MCCLUSKIE et al., "Mucosal immunization with DNA vaccines", <i>Microbes and Infection</i> , 1(9): 685-98, 1999.		
	C136	MCCLUSKIE et al., "Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution", <i>Molecular Medicine</i> , 6(10): 867-77, 2000.		
	C137	MCCLUSKIE et al., "The role of CpG in DNA vaccines", <i>Springer Seminars in Immunopathology</i> , 22(1-2): 125-32, 2000.		
	C138	MCINTYRE et al., "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation", <i>Antisense Research and Development</i> , 3(4): 309-22, 1993.		
	C139	MESSINA et al., "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA", <i>Journal of Immunology</i> , 147(6): 1759-1764, 1991.		
	C140	MICHELSON et al. "Poly(A).poly(U) as adjuvant in cancer treatment distribution and pharmacokinetics in rabbits", <i>Proceedings of Society of Experimental Biological Medicine</i> , 179: 180, 1985.		
	C141	MOLDOVEANU et al., "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus", <i>Vaccine</i> , 16(11-12): 1216-1224, 1998.		
	C142	NEW ENGLAND BIOLABS, 1988-1989 Catalog.		
	C143	NYCE et al., "DNA antisense therapy for asthma in an animal model", <i>Nature</i> , 385: 721-725, 1997.		
	C144	OKADA et al., "Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms", <i>International Journal of Cancer</i> , 78(2): 196-201, 1998.		
	C145	PAL et al., "Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge", <i>Infection and Immunity</i> , 70(9): 4812-7, 2002.		
	C146	PARK et al. "Adjuvant effect of polyadenylic.polyuridylic acid on antibody production of recombinant hepatitis B surface antigen in mice", <i>International Journal of Immunopharmacology</i> , 17(6): 513, 1995.		
	C147	PAYETTE et al., "History of vaccines and positioning of current trends", <i>Current Drugs Targets for Infection and Disorders</i> , 1(3): 241-7, 2001.		
	C148	PISETSKY et al., "The immunologic properties of DNA", <i>Journal of Immunology</i> , 156(2): 421-3, 1996.		
	C149	PISETSKY et al., "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus", <i>Life Sciences</i> , 54(2): 101-107, 1994.		
	C150	PISETSKY et al., "Immunologic consequences of nucleic acid therapy", <i>Antisense Research and Development</i> , 5(3): 219-225, 1995.		
	C151	PISETSKY et al., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Molecular Biology Reports</i> , 18: 217-221, 1993.		
	C152	PISETSKY et al., "The influence of base sequence on the immunostimulatory properties of DNA", <i>Immunity Research</i> , 19: 35-46, 1999.		
	C153	RANIERI et al., "Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading", <i>Immunology Investigations</i> , 29(2): 121-5, 2000.		
	C154	RAZ et al., "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization", <i>Proceedings of the National Academy of Science USA</i> , 93(10): 5141-5, 1996.		
	C155	ROMAN et al., "Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants", <i>Nature Medicine</i> , 3(8): 849-54, 1997.		
	C156	SAJIC et al., "Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge", <i>Journal of Medical Virology</i> , 71(4): 561-568, 2003.		
	C157	SARMIENTO et al., "In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice", <i>Antisense Research and Development</i> , 4: 99-107, 1994.		
	C158	SATO et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization", <i>Science</i> , 273: 352-354, 1996.		
	C159	SCHWARTZ et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract", <i>Journal of Clinical Investigation</i> , 100(1): 68-73, 1997.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	11	of	12				

	C160	SETHI et al., "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", <i>Lancet</i> , 360: 229-230, 2002.		
	C161	SPARWASSER et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <i>European Journal of Immunology</i> , 28(6): 2045-54, 1998.		
	C162	SPARWASSER et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock", <i>European Journal of Immunology</i> , 27(7): 1671-9, 1997.		
	C163	STACEY et al. "Immunostimulatory DNA as an adjuvant in vaccination against <i>Leishmania major</i> ", <i>Infection and Immunity</i> , 67: 3719-3726, 1999.		
	C164	SUN et al. <i>Journal of Experimental Medicine</i> , 188: 2335, 1998.		
	C165	SUN et al. <i>Springer Seminars in Immunopathology</i> , 22: 77, 2000.		
	C166	TALMADGE et al., "Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose", <i>Cancer Research</i> , 45(3): 1058-65, 1985.		
	C167	THREADGILL et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> , 16(1): 76-82, 1998.		
	C168	TOKUNAGA et al., "A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth", <i>Japan Journal of Cancer Research</i> , 79(6): 682-6, 1988.		
	C169	TOKUNAGA et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells", <i>Microbiological Immunology</i> , 36(1): 55-66, 1992.		
	C170	VANDERLUGT et al., "Epitope spreading in immune-mediated diseases: implications for immunotherapy", <i>Nature Reviews in Immunology</i> , 2(2): 85-95, 2002.		
	C171	WAAG et al., "Injection of inactivated phase I <i>Coxiella burnetii</i> increases non-specific resistance to infection and stimulates lymphokine production in mice", <i>Annual New York Academy of Science</i> , 590: 203-214, 1990.		
	C172	WALKER et al., <i>Proceedings of the National Academy of Science, USA</i> , 96: 6970-6975, 1999.		
	C173	WARREN et al., "APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells", <i>Journal of Immunology</i> , 165: 6244, 2000.		
	C174	WEERATNA et al., "Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides", <i>Antisense & Nucleic Drug Development</i> , 8: 351-356, 1998.		
	C175	WEERATNA et al., "CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice", <i>Immunology Cell Biology</i> , 81(1): 59-62, 2003.		
	C176	WEERATNA et al., "CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice", <i>FEMS Immunology Medicine Microbiology</i> , 32(1): 65-71, 2001.		
	C177	WEERATNA et al., "CpG DNA induces stronger immune responses with less toxicity than other adjuvants", <i>Vaccine</i> , 18(17): 1755-62, 2000.		
	C178	WEERATNA et al., "Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies", <i>FEMS Immunology Medicine Microbiology</i> , 30(3): 241-7, 2001.		
	C179	WEINER et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", <i>Proceedings of the National Academy of Science USA</i> , 94(20): 10833-7, 1997.		
	C180	WERNETTE et al., "CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation", <i>Veterinary Immunology and Immunopathology</i> , 84(3-4): 223-236, 2002.		
	C181	WOOLDRIDGE et al. <i>Proceedings of American Association for Cancer Research</i> , 37: 477, 1996.		
	C182	WOOLDRIDGE et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", <i>Blood</i> , 89(8): 2994-2998, 1997.		
	C183	WU et al., "Receptor-mediated gene delivery and expression in vivo", <i>Journal of Biological Chemistry</i> , 263: 14621-14624, 1988.		
	C184	WYATT et al. "Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion", <i>Proceedings of the National Academy of Science USA</i> , 91: 1356-60, 1994.		
	C185	YAMAMOTO et al., "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity", <i>Microbiological Immunology</i> , 38(10): 831-836, 1994.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/735,592		ATTY. DOCKET NO.: C1037.70038US01	
				FILING DATE: December 11, 2003		CONFIRMATION NO.: 2533	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1632		EXAMINER: Not Yet Assigned	
Sheet	12	of	12				

	C186	YAMAMOTO et al., "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", <i>Journal of Immunology</i> , 148(12): 4072-4076, 1992.		
	C187	YAMAMOTO et al., "[Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG]", <i>Kekkaku</i> , 69(9): 571-4, 1994.		
	C188	YAMAMOTO et al., "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length", <i>Antisense Research and Development</i> , 4(2): 119-123, 1994.		
	C189	YAMAMOTO et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro", <i>Japan Journal of Cancer Research</i> , 85: 775-779, 1994.		
	C190	YI et al. "Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA", <i>Journal of Immunology</i> , 161: 4493, 1998.		
	C191	YI et al., "Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway", <i>Journal of Immunology</i> , 157: 5394-5402, 1996.		
	C192	YI et al., "IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides", <i>Journal of Immunology</i> , 156(2): 558-64, 1996.		
	C193	YI et al. "CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry", <i>Journal of Immunology</i> , 160: 5898, 1998.		
	C194	ZIMMERMANN et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis", <i>Journal of Immunology</i> , 160(8): 3627-3630 1998.		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

**a copy of this patent or patent application is not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]